172 related articles for article (PubMed ID: 35698180)
21. Identification of an at-risk subpopulation with high immune infiltration based on the peroxisome pathway and TIM3 in colorectal cancer.
Yin J; Wang H; Hong Y; Ren A; Wang H; Liu L; Zhao Q
BMC Cancer; 2022 Jan; 22(1):44. PubMed ID: 34996408
[TBL] [Abstract][Full Text] [Related]
22. Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal Cancer.
Chen MH; Chang SC; Lin PC; Yang SH; Lin CC; Lan YT; Lin HH; Lin CH; Lai JI; Liang WY; Lu ML; Yang MH; Chao Y
Oncologist; 2019 Dec; 24(12):1534-1542. PubMed ID: 31292272
[TBL] [Abstract][Full Text] [Related]
23. Multi-Omics Prognostic Signatures Based on Lipid Metabolism for Colorectal Cancer.
Sun Y; Liu B; Chen Y; Xing Y; Zhang Y
Front Cell Dev Biol; 2021; 9():811957. PubMed ID: 35223868
[No Abstract] [Full Text] [Related]
24. TRPM7 is overexpressed in human IBD-related and sporadic colorectal cancer and correlates with tumor grade.
Pugliese D; Armuzzi A; Castri F; Benvenuto R; Mangoni A; Guidi L; Gasbarrini A; Rapaccini GL; Wolf FI; Trapani V
Dig Liver Dis; 2020 Oct; 52(10):1188-1194. PubMed ID: 32505565
[TBL] [Abstract][Full Text] [Related]
25. The epigenetic modifier PBRM1 restricts the basal activity of the innate immune system by repressing retinoic acid-inducible gene-I-like receptor signalling and is a potential prognostic biomarker for colon cancer.
Shu XS; Zhao Y; Sun Y; Zhong L; Cheng Y; Zhang Y; Ning K; Tao Q; Wang Y; Ying Y
J Pathol; 2018 Jan; 244(1):36-48. PubMed ID: 28940253
[TBL] [Abstract][Full Text] [Related]
26. Integrative Gene Expression Profiling Analysis to Investigate Potential Prognostic Biomarkers for Colorectal Cancer.
Liu X; Bing Z; Wu J; Zhang J; Zhou W; Ni M; Meng Z; Liu S; Tian J; Zhang X; Li Y; Jia S; Guo S
Med Sci Monit; 2020 Jan; 26():e918906. PubMed ID: 31893510
[TBL] [Abstract][Full Text] [Related]
27. Distinct clinicohistologic features of inflammatory bowel disease-associated colorectal adenocarcinoma: in comparison with sporadic microsatellite-stable and Lynch syndrome-related colorectal adenocarcinoma.
Liu X; Goldblum JR; Zhao Z; Landau M; Heald B; Pai R; Lin J
Am J Surg Pathol; 2012 Aug; 36(8):1228-33. PubMed ID: 22790862
[TBL] [Abstract][Full Text] [Related]
28. Identification and validation of prognosis-associated DNA repair gene signatures in colorectal cancer.
Song D; Zhang D; Chen S; Wu J; Hao Q; Zhao L; Ren H; Du N
Sci Rep; 2022 Apr; 12(1):6946. PubMed ID: 35484177
[TBL] [Abstract][Full Text] [Related]
29. Identification of an Immune Signature Predicting Prognosis Risk and Lymphocyte Infiltration in Colon Cancer.
Li X; Wen D; Li X; Yao C; Chong W; Chen H
Front Immunol; 2020; 11():1678. PubMed ID: 33013820
[TBL] [Abstract][Full Text] [Related]
30. Integrated Analysis of Expression and Prognostic Values of Acyl-CoA Dehydrogenase short-chain in Colorectal Cancer.
Wu Q; Yan T; Chen Y; Chang J; Jiang Y; Zhu D; Wei Y
Int J Med Sci; 2021; 18(16):3631-3643. PubMed ID: 34790035
[No Abstract] [Full Text] [Related]
31. Combination of lysine-specific demethylase 6A (KDM6A) and mismatch repair (MMR) status is a potential prognostic factor in colorectal cancer.
Chen X; Yang Z; Feng J; Duan T; Pan T; Yan L; Jin T; Xiang Y; Zhang M; Chen P; Wang W; Zhang R; Chen B; Zhao L; Xie T; Sui X
Cancer Med; 2021 Jan; 10(1):317-324. PubMed ID: 33174323
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Risk Model of Immune-Related Genes in Colorectal Cancer.
Qian Y; Wei J; Lu W; Sun F; Hwang M; Jiang K; Fu D; Zhou X; Kong X; Zhu Y; Xiao Q; Hu Y; Ding K
Front Genet; 2021; 12():619611. PubMed ID: 33747044
[TBL] [Abstract][Full Text] [Related]
33. Identification and Validation of Six Autophagy-related Long Non-coding RNAs as Prognostic Signature in Colorectal Cancer.
Cheng L; Han T; Zhang Z; Yi P; Zhang C; Zhang S; Peng W
Int J Med Sci; 2021; 18(1):88-98. PubMed ID: 33390777
[TBL] [Abstract][Full Text] [Related]
34. Whole blood ACTB, B2M and GAPDH expression reflects activity of inflammatory bowel disease, advancement of colorectal cancer, and correlates with circulating inflammatory and angiogenic factors: Relevance for real-time quantitative PCR.
Bednarz-Misa I; Neubauer K; Zacharska E; Kapturkiewicz B; Krzystek-Korpacka M
Adv Clin Exp Med; 2020 May; 29(5):547-556. PubMed ID: 32424999
[TBL] [Abstract][Full Text] [Related]
35. Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis.
Kim ER; Chang DK
World J Gastroenterol; 2014 Aug; 20(29):9872-81. PubMed ID: 25110418
[TBL] [Abstract][Full Text] [Related]
36. Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, long-term survey.
Baars JE; Kuipers EJ; van Haastert M; Nicolaï JJ; Poen AC; van der Woude CJ
J Gastroenterol; 2012 Dec; 47(12):1308-22. PubMed ID: 22627504
[TBL] [Abstract][Full Text] [Related]
37. New Methylation Biomarker Panel for Early Diagnosis of Dysplasia or Cancer in High-Risk Inflammatory Bowel Disease Patients.
Azuara D; Aussó S; Rodriguez-Moranta F; Guardiola J; Sanjuan X; Lobaton T; Boadas J; Piqueras M; Monfort D; Guinó E; Moreno V; Capellá G; de Oca J
Inflamm Bowel Dis; 2018 Nov; 24(12):2555-2564. PubMed ID: 30099509
[TBL] [Abstract][Full Text] [Related]
38. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
39. Molecular Alterations of Colorectal Cancer with Inflammatory Bowel Disease.
Yashiro M
Dig Dis Sci; 2015 Aug; 60(8):2251-63. PubMed ID: 25840920
[TBL] [Abstract][Full Text] [Related]
40. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.
Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
